title: Why castration-resistant prostate cancer patients with neuroendocrine differentiation should be addressed to a cisplatin-based regimen.
authors.forename: F
authors.initials: F
authors.lastname: Vignani
authors.forename: L
authors.initials: L
authors.lastname: Russo
authors.forename: M
authors.initials: M
authors.lastname: Tucci
authors.forename: M
authors.initials: M
authors.lastname: Motta
authors.forename: G
authors.initials: G
authors.lastname: Vellani
authors.forename: M
authors.initials: M
authors.lastname: Tampellini
authors.forename: M
authors.initials: M
authors.lastname: Papotti
authors.forename: L
authors.initials: L
authors.lastname: Dogliotti
authors.forename: A
authors.initials: A
authors.lastname: Berruti
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002454:Cell Differentiation; D002945:Cisplatin / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D055099:Neuroendocrine Cells / Q000473:pathology*; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000473:pathology / Q000601:surgery*
chemical_list: D000970:Antineoplastic Agents; D002945:Cisplatin